VYNE Therapeutics, Inc.

As of March 9, 2023, VYNE Therapeutics, Inc. is considered overvalued with significant financial concerns, reflected in a price to book value of 0.38, an EV to EBITDA ratio of 0.74, a troubling -95.55% return on equity, and a year-to-date stock performance decline of -72.71%.

As of May 8, 2025, VYNE Therapeutics, Inc. shows a significant bearish outlook, supported by bearish MACD, moving averages, and Bollinger Bands across weekly and monthly charts.

As of March 2022, the management team of VYNE Therapeutics, Inc. includes CEO David Domzalski, Directors Sharon Barbari, Rex Bright, Anthony Bruno, Independent Directors Patrick LePore and Elisabeth Sandoval, who oversee the company's strategic direction and operations.

VYNE Therapeutics, Inc. is a biopharmaceutical company focused on developing treatments for pruritus related to dermatologic conditions, with a market cap of $15.31 million and recent net sales of $0 million. The company is currently operating at a loss, with a net profit of -$9 million as of March 2025.

As of Jun 18, VYNE Therapeutics, Inc. has a market capitalization of 15.31 million and reported net sales of 0.60 million with a net profit of -42.16 million over the latest four quarters. Shareholder's funds are 52.09 million, and total assets amount to 66.91 million.